Business Context and Reporting Period
Company: OraSure Technologies, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: June 25, 2009
Context: The filing serves as a Regulation FD disclosure to provide an update on clinical development programs and recent manufacturing issues affecting the OraQuick ADVANCE Rapid HIV-1/2 Antibody Test.
Financial Metrics
This filing does not contain financial statements, revenue figures, profit data, cash flow metrics, debt levels, or liquidity information. The document is a current report focused on operational updates rather than financial performance.
Material Changes
The filing reports material operational developments regarding the OraQuick ADVANCE Rapid HIV-1/2 Antibody Test, specifically:
- Updates on clinical development programs.
- Recent manufacturing issues experienced with the product.
Guidance, Outlook, and Risks
Management Commentary: The Company issued a press release (attached as Exhibit 99.1) detailing the status of the aforementioned clinical and manufacturing matters.
Forward-Looking Statements: The Company explicitly states it undertakes no duty or obligation to publicly update or revise the information contained in this report.
Risks and Contingencies: The filing highlights manufacturing issues as a significant operational contingency affecting a key product line.
Key Facts for Investor Verification
- Review the attached press release (Exhibit 99.1) for specific details on the nature and severity of the manufacturing issues.
- Verify the impact of these manufacturing issues on product supply and revenue recognition in subsequent financial filings.
- Monitor updates on the clinical development programs mentioned in the press release.
- Note that this 8-K does not include financial data; refer to the most recent 10-Q or 10-K for financial metrics.